V. Hébert
Impact in
-
- Autoimmune Bullous Skin Diseases
- Dermatology top 5%
- Dermatology and Skin Diseases
- Dermatological and COVID-19 studies
Papers in
-
- Autoimmune Bullous Skin Diseases 41
- Urology 4
- Hair Growth and Disorders 4
- Co-authors
- P. Joly (33 shared papers)Sébastien Calbo (11 shared papers)Olivier Boyer (10 shared papers)Maud Maho‐Vaillant (12 shared papers)Marie-Laure Golinski (11 shared papers)Gaëtan Riou (3 shared papers)Billal Tedbirt (7 shared papers)GUILLAUME CHABY (2 shared papers)
In The Last Decade
V. Hébert
53 papers receiving 1.1k citations
V. Hébert's Hit Papers
Peers
Comparison fields: 5 of 47
- Pathology and Forensic Medicine 887
- Dermatology 61
- Immunology 62
- Infectious Diseases 54
- Rheumatology 31
Countries citing papers authored by V. Hébert
This map shows the geographic impact of V. Hébert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Hébert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Hébert more than expected).
Fields of papers citing papers by V. Hébert
This network shows the impact of papers produced by V. Hébert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Hébert. The network helps show where V. Hébert may publish in the future.
Co-authors
The 25 scholars most cited alongside V. Hébert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 62 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial Hit paper breakdown → | 2017 | 452 |
| 2 | 2019 | 74 | |
| 3 | 2018 | 72 | |
| 4 | 2018 | 66 | |
| 5 | 2020 | 52 | |
| 6 | 2020 | 48 | |
| 7 | 2018 | 42 | |
| 8 | 2019 | 31 | |
| 9 | 2017 | 26 | |
| 10 | 2017 | 22 | |
| 11 | 2019 | 22 | |
| 12 | 2021 | 20 | |
| 13 | 2021 | 20 | |
| 14 | 2021 | 19 | |
| 15 | 2019 | 15 | |
| 16 | 2019 | 15 | |
| 17 | 2020 | 15 | |
| 18 | 2021 | 14 | |
| 19 | 2024 | 14 | |
| 20 | 2019 | 12 |
About V. Hébert
V. Hébert is a scholar working on Pathology and Forensic Medicine, Urology, Pharmacology, Epidemiology and Human-Computer Interaction, having authored 62 papers that have together received 1.2k indexed citations. Recurring topics across this work include Autoimmune Bullous Skin Diseases (41 papers), Drug-Induced Adverse Reactions (4 papers), Hair Growth and Disorders (4 papers), Dermatological diseases and infestations (2 papers), Nail Diseases and Treatments (2 papers), Mosquito-borne diseases and control (2 papers), Dermatological and COVID-19 studies (2 papers) and Pediatric Pain Management Techniques (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (887 citations), Dermatology (61 citations), Immunology (62 citations), Infectious Diseases (54 citations) and Rheumatology (31 citations). V. Hébert has collaborated with scholars based in France, Germany and Japan. Frequent co-authors include P. Joly, Sébastien Calbo, Olivier Boyer, Maud Maho‐Vaillant, Marie-Laure Golinski, Gaëtan Riou, Billal Tedbirt, GUILLAUME CHABY, Michael Hertl and Pascal Reygagne. Their work appears in journals such as British Journal of Dermatology, JAMA Dermatology, Journal of the American Academy of Dermatology, Journal of the European Academy of Dermatology and Venereology and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.